Literature DB >> 33392020

Unusual uptakes on 18F-fluorocholine positron emission tomography/computed tomography (PET/CT): a retrospective study of 368 prostate cancer patients referred for a biochemical recurrence or an initial staging.

Antoine Roland1, Clément Drouet2, Hatem Boulahdour1, Alexandre Cochet2,3, Berardino De Bari4.   

Abstract

BACKGROUND: 18F-fluorocholine positron emission tomography/computed tomography (F-choline PET/CT) is considered a cornerstone in the staging and restaging of patients with prostate cancer (PCa). The aim of this study was to retrospectively assess unusual uptakes in patients who underwent a F-choline PET/CT for the initial staging or for the restaging of a relapsing PCa.
METHODS: Three hundred and sixty-eight PCa patients were staged or restaged using F-choline PET/CT. Unusual uptakes were defined as uptakes occurring outside the usual paths of diffusion of PCa or as uptake in bone with a clear morphological evidence of nonmetastatic lesion.
RESULTS: We found unusual uptakes in 47/368 patients (12.8%). Among them, 41/47 presented with benign F-choline uptake, usually within lymph nodes, due to inflammatory processes (22/47). Other benign processes were found in: thyroid (3/47), adrenal gland (3/47), brain (2/47), liver (1/47), bowel (3/47), frontal sinus (1/47), lungs (4/47), parotid gland (1/47) and bone (1/47). The six remaining patients presented with a second cancer, including lymphoma (1/47), non-small cell lung cancer (4/47) and neuroendocrine tumor (1/47).
CONCLUSIONS: unusual uptakes on F-choline PET/CT are quite frequent and should be explored since they may correspond to non-PCa. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  18F-fluorocholine (F-choline); incidentaloma; positron emission tomography/computed tomography (PET/CT); prostate cancer (PCa)

Year:  2021        PMID: 33392020      PMCID: PMC7719929          DOI: 10.21037/qims-19-981

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  46 in total

Review 1.  Applications of PET imaging with radiolabelled choline (11C/18F-choline).

Authors:  M Kirienko; M Sollini; E Lopci; A Versari; A Chiti
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 2.346

2.  Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18FDG PET/CT in a Patient With Prostate Cancer: Reply.

Authors:  Aurore Goineau; Stéphane Supiot
Journal:  Clin Nucl Med       Date:  2016-09       Impact factor: 7.794

3.  Use of 18F-choline positron emission tomography/CT in high-risk prostate cancer: a case of solitary adrenal metastasis.

Authors:  Fabio Matrone; Silvio Sivolella; Rita Bellavita; Luciano Casciola; Enrico Giuseppe Cristallini; Cynthia Aristei
Journal:  Tumori       Date:  2015-03-20       Impact factor: 2.098

4.  Thyroid Incidentaloma on 18F-fluorocholine PET/CT and 68Ga-PSMA PET/CT Revealing a Medullary Thyroid Carcinoma.

Authors:  Renaud Ciappuccini; Agathe Edet-Sanson; Virginie Saguet-Rysanek; Mathieu Gauthé; Stéphane Bardet
Journal:  Clin Nucl Med       Date:  2019-08       Impact factor: 7.794

5.  Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

Authors:  Martin Heinisch; Albert Dirisamer; Wolfgang Loidl; Franz Stoiber; Bernhard Gruy; Silke Haim; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

6.  Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease.

Authors:  Jean-Noël Talbot; Laetitia Fartoux; Sona Balogova; Valérie Nataf; Khaldoun Kerrou; Fabrice Gutman; Virginie Huchet; David Ancel; Jean-Didier Grange; Olivier Rosmorduc
Journal:  J Nucl Med       Date:  2010-10-18       Impact factor: 10.057

7.  Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers.

Authors:  Ana Ramírez de Molina; Agustín Rodríguez-González; Ruth Gutiérrez; Luis Martínez-Piñeiro; José Sánchez; Félix Bonilla; Rafael Rosell; Juan Lacal
Journal:  Biochem Biophys Res Commun       Date:  2002-08-23       Impact factor: 3.575

Review 8.  (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.

Authors:  Shankar Vallabhajosula
Journal:  Semin Nucl Med       Date:  2007-11       Impact factor: 4.446

Review 9.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis.

Authors:  A M Hövels; R A M Heesakkers; E M Adang; G J Jager; S Strum; Y L Hoogeveen; J L Severens; J O Barentsz
Journal:  Clin Radiol       Date:  2008-02-04       Impact factor: 2.350

Review 10.  Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis.

Authors:  Giorgio Treglia; Salvatore Annunziata; Daniele A Pizzuto; Luca Giovanella; John O Prior; Luca Ceriani
Journal:  Cancers (Basel)       Date:  2019-05-23       Impact factor: 6.639

View more
  3 in total

1.  Value of transrectal contrast-enhanced ultrasound with clinical indicators in the prediction of bone metastasis in prostate cancer.

Authors:  Hua Hong; Danyan Liang; Qian Liu; Guozhu Wu; Ran Sun; Juzhen Liu; Feng Wang; Fang Wang
Journal:  Quant Imaging Med Surg       Date:  2022-03

Review 2.  The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence.

Authors:  Jie Jiang; Xiaoxia Tang; Yongzhu Pu; Yong Yang; Conghui Yang; Fake Yang; Yadong Tian; Jindan Li; Hua Sun; Sheng Zhao; Long Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-27       Impact factor: 6.055

3.  Thyroid 18F-fluorocholine uptake in patients with chronic autoimmune thyroiditis.

Authors:  Renaud Ciappuccini; Virginie Saguet-Rysanek; Marine Dorbeau; Justine Lequesne; Camille Linard; Sophie Lefevre-Arbogast; Bénédicte Clarisse; Stéphane Bardet
Journal:  Eur Thyroid J       Date:  2022-06-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.